Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone augmentation in depression
NCT01375920Phase 3Completed
- Start
- Feb 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Metyrapone with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 5 weeks. Started Feb 2011; status: completed.
02
Drugs
metyrapone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01375920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375920.